Transplantation of Mesenchymal Stem Cells in Multiple Sclerosis

Odinak, M. M.; Бисага, Г Н; Novitskii, A. V.; Тыренко, В В; Фоминых, М. С.; Билибина, А. А.; Kruglyakov, P. V.; Polyntsev, D. G.

doi:10.1007/s11055-012-9593-z

Cited by 11 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous clinical studies, the optimal route of stem cell injection, frequency, and number of cells injected has varied and is yet to be determined . In a preclinical study, direct intraventricular MSCs injection has been reported to be more effective in the EAE model compared to the intravenous route .…”

Section: Discussionmentioning

confidence: 99%

“…In another in vivo study, MSC‐CM attenuated neural degeneration in a spinocerebellar ataxia mice model . A number of promising clinical trials using different sources, doses, and routes of MSCs injections have been conducted, none of them investigated the clinical implications of injecting MSCs‐CM . Thus examining the clinical reproducibility of the encouraging preclinical evidence of the benefits of MSC‐CM is necessary.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy

et al. 2017

View full text Add to dashboard Cite

SummaryAimsThis open‐label prospective phase I/IIa clinical study used autologous bone marrow‐derived mesenchymal stromal cells (BM‐MSCs) followed by mesenchymal stromal cells conditioned media (MSC‐CM) for the first time to treat multiple sclerosis (MS) patients. The primary goal was to assess the safety and feasibility and the secondary was efficacy. The correlation between the MSC‐CM content and treatment outcome was investigated.MethodsTen MS patients who failed conventional therapy were enrolled. Adverse events were recorded to assess safety. The Expanded Disability Status Scale (EDSS) was the primary efficacy measurement, the secondary included clinical (25WFT, 9‐PHT), cognitive (MMS), ophthalmology (OCT, VEP), and radiological (MRI lesion and volume) tests. The MSCs‐CM concentration of 27 inflammatory biomarkers was investigated.ResultsThe treatment protocol was well tolerated by patients. There was an overall trend of improvement in all the tests, except the lesion volume which increased significantly. A decrease of 4 and 3.5 points on the EDSS was achieved in two patients. We report a correlation between a decreased lesion number at baseline and higher IL‐6, IL‐8, and VEGF MSC‐CM content.ConclusionThe used protocol was safe and feasible with possible efficacy. The addition of MSC‐CM could be related to the magnitude of EDSS improvement observed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Cell therapy delivered systemically (as with any conventional drug) may have more rationale—and is safer. Most studies of MSCs have adopted intravenous injection ( Rice et al , 2010 ; Odinak et al , 2011 ; Connick et al , 2012 ; Li et al , 2014 ; Llufriu et al , 2014 ; Lublin et al , 2014 ; Cohen et al , 2017 ). Following intravenous injection, many cells are trapped in the lungs, but significant numbers still enter the CNS, become widely distributed, and can remain for decades, as shown in experimental models and in human subjects ( Cogle et al , 2004 ).…”

Section: Enhanced Endogenous Cell Therapy Including Mesenchymal Stem mentioning

confidence: 99%

Cell-based therapeutic strategies for multiple sclerosis

Scolding

Pasquini

Reingold

et al. 2017

Brain

142

View full text Add to dashboard Cite

show abstract

“…In another study, autologous stem cells were intravenously injected to 8 patients with MS. The outcome was promising together with some positive effects without significant side effects [98].…”

Section: Treatment Of Patients With Ms Using Mesenchymal Stem Cells (mentioning

confidence: 90%

Immunomodulatory Effect of Mesenchymal Stem Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: A Review Study

Naraghi

Hashemi

2018

View full text Add to dashboard Cite

Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system that may lead to disability of the patient. Current MS treatment regimens are still insufficient and research is conducted for developing more effective therapies capable of targeting neurodegeneration, inflammation, and demyelination. Recent results of experimental and clinical studies in cell-based therapy suggest Mesenchymal Stem Cells (MSCs) as potential candidates in autoimmune disorders. Immunomodulatory and neuroprotective properties of mesenchymal stem cells might offer the valuable therapeutic potential to modulate inflammatory responses associated with MS and repairing damaged nervous tissue. This review summarizes the main experimental studies and clinical trials using MSCs in MS.

show abstract

Transplantation of Mesenchymal Stem Cells in Multiple Sclerosis

Cited by 11 publications

References 20 publications

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy

Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy

Cell-based therapeutic strategies for multiple sclerosis

Immunomodulatory Effect of Mesenchymal Stem Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: A Review Study

Contact Info

Product

Resources

About